Probi AB (publ) (PROB.ST)
SEK 347.0
(-0.29%)
SEK 347.0
(-0.29%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 627.68 Million SEK | 1.52% |
| 2022 | 618.28 Million SEK | -6.06% |
| 2021 | 658.18 Million SEK | -8.22% |
| 2020 | 717.16 Million SEK | 14.53% |
| 2019 | 626.19 Million SEK | 3.65% |
| 2018 | 604.11 Million SEK | -1.33% |
| 2017 | 612.24 Million SEK | 37.99% |
| 2016 | 443.69 Million SEK | 105.43% |
| 2015 | 215.98 Million SEK | 56.79% |
| 2014 | 137.75 Million SEK | 33.02% |
| 2013 | 103.55 Million SEK | 3.15% |
| 2012 | 100.39 Million SEK | 6.37% |
| 2011 | 94.37 Million SEK | 17.41% |
| 2010 | 80.38 Million SEK | 22.78% |
| 2009 | 65.46 Million SEK | -3.67% |
| 2008 | 67.95 Million SEK | 55.98% |
| 2007 | 43.56 Million SEK | 17.07% |
| 2006 | 37.21 Million SEK | -32.22% |
| 2005 | 54.9 Million SEK | -13.69% |
| 2004 | 63.61 Million SEK | 15.13% |
| 2003 | 55.25 Million SEK | 2.31% |
| 2002 | 54 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 143.71 Million SEK | -19.66% |
| 2024 Q1 | 151.67 Million SEK | -2.85% |
| 2024 Q2 | 178.88 Million SEK | 17.94% |
| 2023 Q3 | 156.03 Million SEK | 8.57% |
| 2023 Q2 | 143.71 Million SEK | -16.36% |
| 2023 Q4 | 156.12 Million SEK | 0.06% |
| 2023 Q1 | 171.81 Million SEK | 19.33% |
| 2023 FY | 627.68 Million SEK | 1.52% |
| 2022 Q3 | 145.07 Million SEK | -16.87% |
| 2022 Q2 | 174.51 Million SEK | 12.79% |
| 2022 FY | 618.28 Million SEK | -6.06% |
| 2022 Q4 | 143.98 Million SEK | -0.75% |
| 2022 Q1 | 154.71 Million SEK | -9.01% |
| 2021 Q4 | 170.03 Million SEK | 7.03% |
| 2021 Q1 | 171.31 Million SEK | -7.28% |
| 2021 Q2 | 157.96 Million SEK | -7.79% |
| 2021 Q3 | 158.86 Million SEK | 0.57% |
| 2021 FY | 658.18 Million SEK | -8.22% |
| 2020 Q3 | 194.64 Million SEK | 8.15% |
| 2020 Q2 | 179.98 Million SEK | 14.08% |
| 2020 FY | 717.16 Million SEK | 14.53% |
| 2020 Q1 | 157.76 Million SEK | -5.04% |
| 2020 Q4 | 184.76 Million SEK | -5.08% |
| 2019 Q2 | 180.29 Million SEK | 30.49% |
| 2019 Q1 | 138.16 Million SEK | -15.16% |
| 2019 Q3 | 141.59 Million SEK | -21.47% |
| 2019 Q4 | 166.13 Million SEK | 17.34% |
| 2019 FY | 626.19 Million SEK | 3.65% |
| 2018 Q3 | 168.82 Million SEK | 10.17% |
| 2018 Q1 | 119.2 Million SEK | -0.13% |
| 2018 FY | 604.11 Million SEK | -1.33% |
| 2018 Q4 | 162.85 Million SEK | -3.54% |
| 2018 Q2 | 153.23 Million SEK | 28.55% |
| 2017 Q3 | 133.5 Million SEK | -22.38% |
| 2017 Q2 | 171.98 Million SEK | -8.22% |
| 2017 Q1 | 187.4 Million SEK | -1.67% |
| 2017 Q4 | 119.35 Million SEK | -10.6% |
| 2017 FY | 612.24 Million SEK | 37.99% |
| 2016 Q3 | 90.08 Million SEK | 20.52% |
| 2016 Q1 | 88.28 Million SEK | 177.21% |
| 2016 FY | 443.69 Million SEK | 105.43% |
| 2016 Q4 | 190.58 Million SEK | 111.55% |
| 2016 Q2 | 74.74 Million SEK | -15.33% |
| 2015 Q3 | 52.63 Million SEK | -11.91% |
| 2015 Q2 | 59.75 Million SEK | -16.71% |
| 2015 Q4 | 31.84 Million SEK | -39.5% |
| 2015 FY | 215.98 Million SEK | 56.79% |
| 2015 Q1 | 71.74 Million SEK | 75.21% |
| 2014 Q4 | 40.94 Million SEK | 8.04% |
| 2014 FY | 137.75 Million SEK | 33.02% |
| 2014 Q3 | 37.89 Million SEK | 17.49% |
| 2014 Q2 | 32.25 Million SEK | 21.03% |
| 2014 Q1 | 26.65 Million SEK | 0.94% |
| 2013 Q2 | 26.93 Million SEK | 4.85% |
| 2013 Q1 | 25.68 Million SEK | -2.49% |
| 2013 FY | 103.55 Million SEK | 3.15% |
| 2013 Q4 | 26.4 Million SEK | 7.64% |
| 2013 Q3 | 24.52 Million SEK | -8.93% |
| 2012 Q3 | 20.9 Million SEK | -5.94% |
| 2012 FY | 100.39 Million SEK | 6.37% |
| 2012 Q1 | 30.63 Million SEK | 24.74% |
| 2012 Q2 | 22.22 Million SEK | -27.46% |
| 2012 Q4 | 26.34 Million SEK | 26.01% |
| 2011 Q2 | 24.02 Million SEK | 0.19% |
| 2011 Q3 | 21.93 Million SEK | -8.72% |
| 2011 Q4 | 24.56 Million SEK | 11.98% |
| 2011 FY | 94.37 Million SEK | 17.41% |
| 2011 Q1 | 23.98 Million SEK | 9.66% |
| 2010 Q1 | 15.93 Million SEK | 0.0% |
| 2010 FY | 80.38 Million SEK | 22.78% |
| 2010 Q3 | 26.65 Million SEK | 66.99% |
| 2010 Q4 | 21.86 Million SEK | -17.97% |
| 2010 Q2 | 15.96 Million SEK | 0.16% |
| 2009 FY | 65.46 Million SEK | -3.67% |
| 2008 FY | 67.95 Million SEK | 55.98% |
| 2007 FY | 43.56 Million SEK | 17.07% |
| 2006 FY | 37.21 Million SEK | -32.22% |
| 2005 FY | 54.9 Million SEK | -13.69% |
| 2004 FY | 63.61 Million SEK | 15.13% |
| 2003 FY | 55.25 Million SEK | 2.31% |
| 2002 FY | 54 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AcuCort AB | - SEK | -Infinity% |
| AlzeCure Pharma AB (publ) | - SEK | -Infinity% |
| BioGaia AB (publ) | 1.29 Billion SEK | 51.586% |
| Enzymatica AB (publ) | 50.9 Million SEK | -1133.08% |
| Enorama Pharma AB (publ) | 1.35 Million SEK | -46121.429% |
| Gabather AB (publ) | - SEK | -Infinity% |
| Klaria Pharma Holding AB (publ.) | - SEK | -Infinity% |
| Moberg Pharma AB (publ) | - SEK | -Infinity% |
| Nanexa AB (publ) | 29.32 Million SEK | -2040.304% |
| Newbury Pharmaceuticals AB (publ) | 36.82 Million SEK | -1604.328% |
| ODI Pharma AB | 22.44 Million SEK | -2696.291% |
| Orexo AB (publ) | 638.8 Million SEK | 1.74% |
| Swedencare AB (publ) | 2.32 Billion SEK | 72.998% |
| Swedish Orphan Biovitrum AB (publ) | 22.12 Billion SEK | 97.163% |
| Toleranzia AB | 50.92 Million SEK | -1132.692% |
| Vivesto AB | 1.01 Million SEK | -61741.084% |